Head and Neck Cancer

PV QA 2 - Poster Viewing Q&A 2

MO_35_2835 - Outcomes after Salvage Therapy in Oral Cavity Squamous Cell Carcinoma (OCSCC) Patients Who Developed Locoregional Failure (LRF) after Definitive Surgery and Adjuvant (chemo)Radiotherapy: A Multi-Institutional Collaborative Study

Monday, October 22
10:45 AM - 12:15 PM
Location: Innovation Hub, Exhibit Hall 3

Outcomes after Salvage Therapy in Oral Cavity Squamous Cell Carcinoma (OCSCC) Patients Who Developed Locoregional Failure (LRF) after Definitive Surgery and Adjuvant (chemo)Radiotherapy: A Multi-Institutional Collaborative Study
C. J. Tsai1, P. Xie2, N. M. Woody3, X. Li2, S. M. McBride1, J. J. Caudell4, A. I. Ghanem5, H. Liu6, N. P. Joshi3, J. L. Geiger7, E. Lamarre8, M. A. Schymick5, L. Tam6, B. B. Burkey8, D. J. Adelstein7, N. E. Dunlap9, S. Porceddu10, F. Siddiqui5, S. Koyfman3, and N. Lee1; 1Memorial Sloan Kettering Cancer Center, Department of Radiation Oncology, New York, NY, 2Shandong Cancer Hospital Affiliated to Shandong University, Shandong Academy of Medical Sciences, Jinan, China, 3Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, 4H. Lee Moffitt Cancer Center and Research Institute, Department of Radiation Oncology, Tampa, FL, 5Henry Ford Health System, Detroit, MI, 6Princess Alexandra Hospital, Woolloongabba, Australia, 7Department of Hematology/Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, 8Department of Otolaryngology, Head and Neck Institute, Cleveland Clinic, Cleveland, OH, 9University of Louisville Hospital, Department of Radiation Oncology, Louisville, KY, 10Princess Alexandra Hospital/University of Queensland, Brisbane, Australia

Purpose/Objective(s): We conducted a multi-institutional study to review salvage therapy outcomes in OCSCC patients who developed LRF after upfront surgery and adjuvant (chemo)radiotherapy.

Materials/Methods: A collaborative patient database with primary OCSCC stage I-IVB (AJCC 7th Ed) treated with primary surgical resection between 1/1/2005 and 1/1/2015 was collected from 6 academic centers. From a total of 1282 patients, we identified patients who developed LRF after primary surgery and adjuvant (chemo)radiotherapy. The exclusion criteria were: missing information on LRF, distant failure within 30 days of LRF, and LRF before completing initial adjuvant therapy. Cox proportional hazard analysis was performed to estimate hazard ratio (HR).

Results: 156 patients were selected: 60 females (38%), 126 Caucasians (81%), and 63 (40%) oral tongue primaries. Median age at initial diagnosis was 61 years. 152 (97%) smoked or chewed tobacco and 103 (66%) used alcohol. 54 (34 %) had pT4 and 76 (49%) pN2b-c disease. 33 (21%) had a positive margin at the initial surgery and 55 (15%) had extranodal spread. All received adjuvant radiation with a median dose of 60Gy and 66 (42%) patients also had concurrent chemotherapy. With a median follow up of 22.5 months, 82 (53%) developed only local failure, 39 (25%) had only neck failure, and 35 (22%) had both local and regional nodal failures. The median time to LRF was 13 months (range: 4-130). 104 of 156 (67%) underwent salvage surgery and 28 (27%) of surgically salvaged patients also received adjuvant re-irradiation. Patients who had any regional failure were more likely to receive adjuvant re-irradiation than those without (88% vs 11%, p=0.001). 49 (31%) patients received salvage chemotherapy. 38 (24%) patients had a 2nd LRF after salvage therapy. Median OS after 1st LRF for all patients was 7.7 months. Time from initial diagnosis to 1st LRF was not associated with OS. In multivariable analysis controlling for age, gender, re-irradiation, and salvage chemotherapy, lack of salvage surgery was independently associated with worse OS (HR=4.3, 95%CI=2.5-7.1). About 30% of surgically salvaged patients were alive at 125 months after 1st LRF. Among those who received salvage surgery, positive surgical margin (HR=2.3, 95%CI=1.1-4.8) and perineural invasion (PNI) (HR=2.3, 95%CI=1.1-4.6) were independently correlated with worse OS. Receipt of adjuvant re-irradiation showed a trend toward more favorable OS (HR=0.5, 95%CI=0.2-1.0) after further accounting for nodal failure status.

Conclusion: Patients who were selected to receive salvage surgery had more favorable outcomes than those who were not. Positive salvage surgical margin and PNI were associated with worse OS. Adjuvant re-irradiation showed a trend towards improved OS after accounting for nodal failure status.

Author Disclosure: C. Tsai: None. P. Xie: None. N.M. Woody: None. X. Li: None. S.M. McBride: None. A.I. Ghanem: None. M.A. Schymick: None. D.J. Adelstein: None. N.E. Dunlap: Honoraria; Osler Institute. F. Siddiqui: Employee; Children's Hospital of Michigan. Research Grant; Varian Medical Systems, Inc. Honoraria; American College of Radiology, Varian Medical Systems, Inc, Wayne State University. Travel Expenses; Varian Medical Systems, Inc. Vice-Chairman or Operations; Department of Radiation Oncology, Henry Ford Hosp. Chair; ASTRO. Board Member; Henry Ford Health System Board of Governors. Committee Member; HFHS Bylaws and Governance Committee. S. Koyfman: Research Grant; Merck. N. Lee: Consultant; Lily. Advisory Board; Pfizer, Vertex, Merck.

C Jillian Tsai, MD, PhD, MS

Memorial Sloan Kettering Cancer Center

Disclosure:
No relationships to disclose.

Biography:
C. Jillian Tsai, MD, PhD
Radiation Oncologist and Director of Head and Neck Radiation Oncology Research
Memorial Sloan Kettering Cancer Center.

I am a board-certified radiation oncologist and epidemiologist with a clinical emphasis on delivering personalized and effective radiation therapy while minimizing treatment-related side effects. My research focuses on population-based cancer studies, cancer epidemiology, radiation-related toxicities, and clinical trials using novel technology/therapeutics. I have a particular interest in HPV- and EBV-associated malignancies, am developing clinical trials that integrate advanced radiation therapy techniques with other novel therapeutics to improve cancer care outcome as well as quality of life for these patients. I have also studied extensively the normal tissue toxicities in relation to radiation dosimetric factors. Additionally, I am interested in developing novel radiation treatment approaches for patients with metastatic disease.

Presentation(s):

Send Email for C Jillian Tsai


Assets

MO_35_2835 - Outcomes after Salvage Therapy in Oral Cavity Squamous Cell Carcinoma (OCSCC) Patients Who Developed Locoregional Failure (LRF) after Definitive Surgery and Adjuvant (chemo)Radiotherapy: A Multi-Institutional Collaborative Study



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Outcomes after Salvage Therapy in Oral Cavity Squamous Cell Carcinoma (OCSCC) Patients Who Developed Locoregional Failure (LRF) after Definitive Surgery and Adjuvant (chemo)Radiotherapy: A Multi-Institutional Collaborative Study